Effects of oral clotrimazole troches on the pharmacokinetics of oral and intravenous midazolam

British Journal of Clinical Pharmacology

Volumn 69, Issue 2, 2010, Pages 160-166

  Shord, Stacy S ^d   Chan, Lingtak Neander ^d   Camp, Joseph R ^d   Vasquez, Eva M ^d   Jeong, Hyun Young ^d   Molokie, Robert E ^a   Baum, Charles L ^b   Xie, Hui ^c  

^a UNIVERSITY OF ILLINOIS   (United States)

^b Center for End of Life Transition Research   (United States)

^c UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^d Chicago College of Pharmacy   (United States)

Author keywords

Clotrimazole; CYP3A4; Drug drug interaction; Extraction; Pharmacokinetics; Ratiomidazolam

Indexed keywords

1 HYDROXYMIDAZOLAM; CLOTRIMAZOLE; DRUG METABOLITE; MIDAZOLAM; UNCLASSIFIED DRUG; ANTIFUNGAL AGENT; ANXIOLYTIC AGENT; CYTOCHROME P450 3A;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFECT; DRUG ELIMINATION; DRUG HALF LIFE; FEMALE; HUMAN; HUMAN EXPERIMENT; MALE; MAXIMUM PLASMA CONCENTRATION; NORMAL HUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; ADOLESCENT; ANALYSIS OF VARIANCE; CROSSOVER PROCEDURE; DRUG INTERACTION; INTRAVENOUS DRUG ADMINISTRATION; METABOLIC CLEARANCE RATE; METABOLISM; MIDDLE AGED; ORAL DRUG ADMINISTRATION;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; ANALYSIS OF VARIANCE; ANTI-ANXIETY AGENTS; ANTIFUNGAL AGENTS; AREA UNDER CURVE; CLOTRIMAZOLE; CROSS-OVER STUDIES; CYTOCHROME P-450 CYP3A; DRUG INTERACTIONS; FEMALE; HUMANS; INJECTIONS, INTRAVENOUS; MALE; METABOLIC CLEARANCE RATE; MIDAZOLAM; MIDDLE AGED;

EID: 75149178776     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2009.03559.x     Document Type: Article

References (43)

1. Gombert ME, duBouchet L, Aulicino TM, Butt KM. A comparative trial of clotrimazole troches and oral nystatin suspension in recipients of renal transplants. Use in prophylaxis of oropharyngeal candidiasis. JAMA 1987 258 : 2553 2555.
2. Owens NJ, Nightingale CH, Schweizer RT, Schauer PK, Dekker PT, Quintiliani R. Prophylaxis of oral candidiasis with clotrimazole troches. Arch Intern Med 1984 144 : 290 293.
3. Ruskin JD, Wood RP, Bailey MR, Whitmore CK, Shaw BW. Comparative trial of oral clotrimazole and nystatin for oropharyngeal candidiasis prophylaxis in orthotopic liver transplant patients. Oral Surg Oral Med Oral Pathol 1992 74 : 567 571.
4. Sadaba B, Campanero MA, Quetglas EG, Azanza JR. Clinical relevance of sirolimus drug interactions in transplant patients. Transplant Proc 2004 36 : 3226 3228.
5. Hyland R, Jones BC, Smith DA. Identification of the cytochrome P450 enzymes involved in the N-oxidation of voriconazole. Drug Metab Dispos 2003 31 : 540 547.
6. Venkatakrishnan K, von Moltke LL, Greenblatt DJ. Effects of the antifungal agents on oxidative drug metabolism: clinical relevance. Clin Pharmacokinet 2000 38 : 111 180.
7. Liu P, Foster G, LaBadie RR, Gutierrez MJ, Sharma A. Pharmacokinetic interaction between voriconazole and efavirenz at steady state in healthy male subjects. J Clin Pharmacol 2008 48 : 73 84.
8. Niwa T, Shiraga T, Takagi A. Effect of antifungal drugs on cytochrome P450 (CYP) 2C9, CYP2C19, and CYP3A4 activities in human liver microsomes. Biol Pharm Bull 2005 28 : 1805 1808. (Pubitemid 41324160)
9. Pea F, Baccarani U, Tavio M, Cojutti P, Adani GL, Londero A, Baraldo M, Franceschi L, Furlanut M, Viale P. Pharmacokinetic interaction between everolimus and antifungal triazoles in a liver transplant patient. Ann Pharmacother 2008 42 : 1711 1716.
10. Saari TI, Laine K, Bertilsson L, Neuvonen PJ, Olkkola KT. Voriconazole and fluconazole increase the exposure to oral diazepam. Eur J Clin Pharmacol 2007 63 : 941 949.
11. Krishna G, Moton A, Ma L, Savant I, Martinho M, Seiberling M, McLeod J. Effects of oral posaconazole on the pharmacokinetic properties of oral and intravenous midazolam: a phase I, randomized, open-label, crossover study in healthy volunteers. Clin Ther 2009 31 : 286 298.
12. Moton A, Ma L, Krishna G, Martinho M, Seiberling M, McLeod J. Effects of oral posaconazole on the pharmacokinetics of sirolimus. Curr Med Res Opin 2009 25 : 701 707.
13. Wexler D, Courtney R, Richards W, Banfield C, Lim J, Laughlin M. Effect of posaconazole on cytochrome P450 enzymes: a randomized, open-label, two-way crossover study. Eur J Pharm Sci 2004 21 : 645 653.
14. Gibbs MA, Kunze KL, Howald WN, Thummel KE. Effect of inhibitor depletion on inhibitory potency: tight binding inhibition of CYP3A by clotrimazole. Drug Metab Dispos 1999 27 : 596 599.
15. Luo G, Cunningham M, Kim S, Burn T, Lin J, Sinz M, et al. CYP3A4 induction by drugs: correlation between a pregnane X receptor reporter gene assay and CYP3A4 expression in human hepatocytes. Drug Metab Dispos 2002 30 : 795 804.
16. Mieles L, Venkataramanan R, Yokoyama I, Warty VJ, Starzl TE. Interaction between FK506 and clotrimazole in a liver transplant recipient. Transplantation 1991 52 : 1086 1087.
17. Vasquez E, Pollak R, Benedetti E. Clotrimazole increases tacrolimus blood levels: a drug interaction in kidney transplant patients. Clin Transplant 2001 15 : 95 9.
18. Schuetz EG, Beck WT, Schuetz JD. Modulators and substrates of P-glycoprotein and cytochrome P4503A coordinately up-regulate these proteins in human colon carcinoma cells. Mol Pharmacol 1996 49 : 311 318.
19. Zhang W, Ramamoorthy Y, Kilicarslan E, Nolte H, Tyndale RF, Sellers EM. Inhibition of cytochrome P450 by antifungal imidazole derivatives. Drug Metab Dispos 2002 30 : 314 318.
20. Hebert MF. Contributions of hepatic and intestinal metabolism and P-glycoprotein to cyclosporine and tacrolimus oral drug delivery. Adv Drug Deliv Rev 1997 27 : 201 214.
21. Pascussi JM, Drocourt L, Fabre JM, Maurel P, Vilarem MJ. Dexamethasone induces pregnane X receptor and retinoid X receptor-alpha expression in human hepatocytes: synergistic increase of CYP3A4 induction by pregnane X receptor activators. Mol Pharmacol 2000 58 : 361 372.
22. Gomez-Lechon MJ, Donato T, Ponsoda X, Castell JV. Human hepatic cell cultures: in vitro and in vivo drug metabolism. Altern Lab Anim 2003 31 : 257 265.
23. Heiskanen T, Backman JT, Neuvonen M, Kontinen VK, Neuvonen PJ, Kalso E. Itraconazole, a potent inhibitor of P-glycoprotein, moderately increases plasma concentrations of oral morphine. Acta Anaesthesiol Scand 2008 52 : 1319 1326.
24. Shimizu M, Uno T, Sugawara K, Tateishi T. Effects of single and multiple doses of itraconazole on the pharmacokinetics of fexofenadine, a substrate of P-glycoprotein. Br J Clin Pharmacol 2006 62 : 372 376.
25. Shimizu M, Uno T, Sugawara K, Tateishi T. Effects of itraconazole and diltiazem on the pharmacokinetics of fexofenadine, a substrate of P-glycoprotein. Br J Clin Pharmacol 2006 61 : 538 544.
26. Angirasa AK, Koch AZ. P-glycoprotein as the mediator of itraconazole-digoxin interaction. J Am Podiatr Med Assoc 2002 92 : 471 472.
27. Jalava KM, Partanen J, Neuvonen PJ. Itraconazole decreases renal clearance of digoxin. Ther Drug Monit 1997 19 : 609 613.
28. Kinirons MT, O'Shea D, Kim RB, Groopman JD, Thummel KE, Wood AJ, Wilkinson GR. Failure of erythromycin breath test to correlate with midazolam clearance as a probe of cytochrome P4503A. Clin Pharmacol Ther 1999 66 : 224 231.
29. Lehmann B, Boulieu R. Determination of midazolam and its unconjugated 1-hydroxy metabolite in human plasma by high-performance liquid chromatography. J Chromatogr B Biomed Appl 1995 674 : 138 142.
30. de Bruijn P, Kehrer DF, Verweij J, Sparreboom A. Liquid chromatographic determination of ketoconazole, a potent inhibitor of CYP3A4-mediated metabolism. J Chromatogr B Biomed Sci Appl 2001 753 : 395 400.
31. Lee JI, Chaves-Gnecco D, Amico JA, Kroboth PD, Wilson JW, Frye RF. Application of semisimultaneous midazolam administration for hepatic and intestinal cytochrome P450 3A phenotyping. Clin Pharmacol Ther 2002 72 : 718 728.
32. Gorski JC, Vannaprasaht S, Hamman MA, Ambrosius WT, Bruce MA, Haehner-Daniels B, et al. The effect of age, sex, and rifampin administration on intestinal and hepatic cytochrome P450 3A activity. Clin Pharmacol Ther 2003 74 : 275 287.
33. Gorski JC, Jones DR, Haehner-Daniels BD, Hamman MA, O'Mara EM Jr., Hall SD. The contribution of intestinal and hepatic CYP3A to the interaction between midazolam and clarithromycin. Clin Pharmacol Ther 1998 64 : 133 143.
34. Smith MT, Eadie MJ, Brophy TO. The pharmacokinetics of midazolam in man. Eur J Clin Pharmacol 1981 19 : 271 278.
35. Cote CJ, Cohen IT, Suresh S, Rabb M, Rose JB, Weldon C, Davis PJ, Bikhazi GB, Karls HW, Hummer KA, Hannallah RS, Khoo KC, Collins P. A comparison of three doses of a commercially prepared oral midazolam syrup in children. Anesth Analg 2002 94 : 37 43.
36. Tsunoda SM, Velez RL, von Moltke LL, Greenblatt DJ. Differentiation of intestinal and hepatic cytochrome P450 3A activity with use of midazolam as an in vivo probe: effect of ketoconazole. Clin Pharmacol Ther 1999 66 : 461 471.
37. Olkkola KT, Backman JT, Neuvonen PJ. Midazolam should be avoided in patients receiving the systemic antimycotics ketoconazole or itraconazole. Clin Pharmacol Ther 1994 55 : 481 485.
38. Ahonen J, Olkkola KT, Neuvonen PJ. Effect of route of administration of fluconazole on the interaction between fluconazole and midazolam. Eur J Clin Pharmacol 1997 51 : 415 419.
39. Ahonen J, Olkkola KT, Takala A, Neuvonen PJ. Interaction between fluconazole and midazolam in intensive care patients. Acta Anaesthesiol Scand 1999 43 : 509 514.
40. Gibbs MA, Kunze KL, Howald WN, Thummel KE. Effect of inhibitor depletion on inhibitory potency: tight binding inhibition of CYP3A by clotrimazole. Drug Metab Dispos 1999 27 : 596 599.
41. Sawamura R, Sato H, Kawakami J, Iga T. Inhibitory effect of azole antifungal agents on the glucuronidation of lorazepam using rabbit liver microsomes in vitro. Biol Pharm Bull 2000 23 : 669 671.
42. Asgari M, Back DJ. Effect of azoles on the glucuronidation of zidovudine by human liver UDP-glucuronosyltransferase. J Infect Dis 1995 172 : 1634 1636.
43. Sampol E, Lacarelle B, Rajaonarison JF, Catalin J, Durand A. Comparative effects of antifungal agents on zidovudine glucuronidation by human liver microsomes. Br J Clin Pharmacol 1995 40 : 83 6.